Shots:
- Rona Therapeutics has granted Roche an exclusive worldwide license to Rona’s RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company’s extrahepatic delivery platform
- As per the deal, Rona will receive ~$100M in upfront & near-term milestone payments, plus ~$1.06B in development, regulatory & commercial milestone payments, as well as tiered royalties on global net sales
- The candidate inhibits ALK7 by directly targeting adipocytes to selectively reduce visceral & ectopic fat while preserving lean mass, offering a differentiated approach that may complement incretin-based therapies
Ref: PRnewswire | Image: Roche & Rona Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
